- Cancer Biology
- Oncology
- Endocrinology
- +۴ مورد دیگر
Dr. Vincent Cryns is a Professor in the Department of Medicine at the University of Wisconsin-Madison School of Medicine and Public Health. He serves as Chief of the Division of Endocrinology, Diabetes and Metabolism and holds the Marian A. and Rodney P. Burgenske Chair in Diabetes Research. His research focuses on cancer metabolism, particularly the connections between metabolic stress and breast cancer progression. He co-leads the Physician-Scientist Training Program (PSTP) and is a member of prestigious organizations like the American Society for Clinical Investigation. Education : MD from Harvard Medical School Internship in Internal Medicine at Massachusetts General Hospital Residency in Internal Medicine at Dartmouth-Hitchcock Medical Center Clinical Fellowship and Research Fellowship in Medicine at Harvard Medical School Research Interests : Dr. Cryns investigates 'third messenger' pathways involving lipid second messengers in the nucleus, particularly how these pathways protect cancer cells from metabolic stress. His lab, the Third Messenger Lab (collaborating with Dr. Richard Anderson), has identified novel drug targets and signaling mechanisms linked to p53 and Akt activation. His work is funded by the NIH, Department of Defense, and the Breast Cancer Research Foundation. Key Contributions : His team discovered that nuclear phosphoinositide kinases and p53 form a signalosome regulating AKT activation, and that alphaB-crystallin promotes cancer metastasis. Recent studies explore metabolic vulnerabilities in triple-negative breast cancer and the role of methionine restriction. Grants & Awards : NIH grants (NCI, NIA) Department of Defense Breast Cancer Research Program National recognition (Best Doctors in America) Media features in Nature, NPR, and Oprah Magazine Labs & Teams : The Cryns Lab actively recruits scientists and focuses on cancer metabolism and third messenger pathways. Collaborations include developing nanoparticulate drug formulations and investigating nuclear phosphoinositide signaling in metastasis.











